1246508-13-3

Upstream product

• 100-46-9 benzylamine 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 1489-97-0 ethyl 1,4-dioxaspiro[4.5]decane-8-carboxylate 
• 1246508-12-2 ethyl 2-(8-(nitromethyl)-1,4-dioxaspiro-[4,5]-decan-8-yl-acetate) 
• 51656-91-8 ethyl 1,4-dioxaspiro[4,5]dec-8-ylideneacetate 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 914780-95-3 1,4-dioxa-10-azadispiro[4.2.4⁸.2⁵]tetradecan-11-one 
• 100-39-0 benzyl bromide 

Downstream Products

• 1246508-14-4 10-benzyl-1,4-dioxa-10-azadispiro[4.2.4⁸.2⁵]tetradecane 

Relevant academic research and scientific papers

FACTOR XIIa INHIBITORS

The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors.

SUBSTITUTED AZASPIRO(4.5)DECANE DERIVATIVES

The invention relates to substituted spirocyclic cyclohexane derivatives which have an affinity for the μ opioid receptor and/or the ORL1 receptor, processes for the preparation thereof, medicaments containing these compounds and the use of these compounds for the preparation of medicaments.

4-quinazoline amine derivatives and their use

A 4-quinazoline amine derivative as represented by formula (1), a pharmaceutical composition comprising the derivative, and an application thereof in preparing medicine for curing cancer. The cancer is a drug-resistant cancer, preferably a cancer resisting an EGFR reversible inhibitor, and more preferably, a cancer resisting gefitinib, erlotinib or lapatinib; alternatively, the cancer carries EGFR mutation.

Substituted Spiro-amide Compounds

Substituted spiro-amide compounds corresponding to formula I in which R5 through R8, D, X, Y and Z have defined meanings, processes for preparing such spiro-amide compounds, pharmaceutical compositions containing such compounds, and methods of using such spiro-amide compounds for treating and/or inhibiting disorders or disease states mediated at least in part by the bradykinin 1 receptor.